Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
YMABY-mAbs(YMAB) ZACKS·2024-08-12 20:40

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of 0.21pershareversustheZacksConsensusEstimateofalossof0.21 per share versus the Zacks Consensus Estimate of a loss of 0.13. This compares to loss of 0.14pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−61.540.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of 0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%.Over the last four quarters, the company has ...